Omeros Corporation

OMER Healthcare Biotechnology

Revenue
+35.5%
EPS
+141.9%
Free cash flow
+118.7%
Total debt
−42.0%

Quarter to June 2026, against a year earlier

16.83 0.24 −1.41%
Market cap
$1.2B
P/E
9.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
2/9
Altman Z
−6.82
Beneish M
−0.06
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
6 5 1 4 2 — — — — —
P/E ratio
0.00 0.00 0.00 0.00 0.00 — — — — —
P/S ratio
9.82 14.16 18.12 6.24 11.07 — — — — —
Altman Z-Score
(8.73) (1.68) (10.72) (8.09) (6.82) — — — — —
Altman Z″-Score (non-manufacturers)
(24.26) (12.60) (26.90) (22.80) (17.81) — — — — —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 — — — — —
Beneish M-Score
(2.25) (2.79) (3.11) (0.06) — — — — — —
P/Operating CF
(37.61) (220.05) (21.95) (30.32) (44.39) — — — — —
P/B ratio
0.00 0.00 0.00 0.00 0.00 — — — — —
EV/Sales
10.64 14.16 21.08 7.14 12.49 — — — — —
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 — — — — —
EV/FCF
(8.57) (25.09) (6.04) (13.22) (9.19) — — — — —
Current Ratio
3.75 4.12 2.41 1.87 4.12 4.79 3.25 4.09 1.69 2.76
Net Debt/EBITDA
(0.64) 0.00 (0.80) (0.70) (0.68) (0.94) (0.75) (0.26) (0.57) (0.30)
Debt/Equity
(2.13) (29.78) (1.50) (1.48) (1.99) 13.40 3.68 (8.53) (1.03) (1.72)
ROE
209.62% 265.67% 246.20% 80.78% 120.17% (400.60%) 86.63% (388.17%) 151.08% 2.21%
ROA
(114.81%) (58.26%) (119.43%) (72.55%) (86.83%) 64.71% 9.39% (24.31%) (47.86%) (1.11%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% (58.58%) (49.56%) (629.94%) 0.00% 0.00%
Return on Tangible Assets
(147.11%) (63.53%) (224.92%) (162.11%) (117.90%) 98.15% 15.38% (70.74%) (273.81%) (2.40%)
Average Days of Receivables
105.57 96.53 278.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(16.34%) (5.80%) (23.43%) (12.07%) (16.79%) — — — — —
Free Cash Flow Yield
(12.65%) (3.98%) (19.27%) (8.66%) (12.28%) — — — — —
Free Cash Flow per Share
(1.28) (0.80) (2.15) (1.22) (1.76) (1.76) (1.38) 1.18 (2.56) (1.83)
Book value per Share
(0.93) (0.06) (2.06) (2.20) (2.11) 0.38 1.37 (0.40) (3.14) (1.91)
Free Cash Flow
(51.63) (36.58) (104.30) (60.41) (100.37) (110.00) (86.60) 74.30 (148.97) (116.16)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 — — — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026